Popular Articles From: Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical and Biological Activity in Adult Patients with Acute Leukemias in Phase 1 Trial to More Drones in 2015, But Not Drone Rules -- Corporate Outlook


Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company’s Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT). Epizyme, along with its partner Celgene, is developing EPZ-5676 for the treatment of acute leukemia with alterations in the MLL gene (MLL-r) or partial tandem duplications within MLL (MLL-PTD). The trial found that EPZ-5676 was generally safe and well tolerated across all dose cohorts and showed clinical and biological activity.
Sign-up for Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical and Biological Activity in Adult Patients with Acute Leukemias in Phase 1 Trial investment picks
2015/1/8
By Friedrich Geiger BERLIN--
Sign-up for Porsche Sales Surge on Demand for Macan, Cayenne SUVs investment picks
2015/1/6
By Gaurav Raghuvanshi And Richard C.
Sign-up for AirAsia Flight 8501 Crash: Time Running Out to Recover Floating Bodies -- 3rd Update investment picks
GENEVA, Switzerland, Nov.
Sign-up for STMicroelectronics Creates World's First Set-Top-Box Platform That Supports Android TV 5.0 Lollipop investment picks
2014/12/12
By Gillian Wong Move by Chinese Internet firm could help Uber's business in China Chinese Internet giant Baidu Inc. will invest in ride-hailing app Uber Technologies Inc., a person familiar with the matter said Friday, in a move that could help the U.S. startup's business in China.
Sign-up for Uber gets investment from Baidu investment picks
2015/1/7
http://media.marketwire.com/attachments/201303/139177_mcdonalds-arches.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1167979&ProfileId=051205&sourceType=1 OAK BROOK, IL --
Sign-up for McDonald's USA Brings Back Happy Meal Books investment picks
Keurig Green Mountain, Inc., (Keurig) (NASDAQ: GMCR), a leader in specialty coffee, coffee makers, teas and other beverages with its innovative brewing technology, today announces that it is now the exclusive manufacturer of Meijer Brand K-Cup ® packs for the Keurig ® hot brewing system.
Sign-up for Keurig Green Mountain Welcomes Meijer K-Cup Packs into the Keurig Brewed Family investment picks
Keurig Green Mountain, Inc. (Keurig) (NASDAQ:GMCR), a leader in specialty coffee, coffee makers, teas and other beverages with its innovative brewing technology, and Community Coffee Company, the largest family owned and operated retail coffee brand in America, announced a multi-year licensing, manufacturing, and distribution agreement to bring Community ® coffee to Keurig ® portion pack formats for consumer and commercial Keurig ® hot brewing systems.
Sign-up for Keurig Green Mountain and Community Coffee Company Announce Partnership investment picks
Keurig Green Mountain, Inc. (Keurig) (NASDAQ: GMCR) and Caribou Coffee announced that the companies have renewed their partnership with a 10-year agreement for the manufacturing, marketing, distribution, and sale of Caribou Coffee in Keurig ® pack formats for Keurig ® consumer and commercial hot brewing systems.
Sign-up for Keurig Green Mountain and Caribou Coffee Announce Expanded Agreement investment picks
2014/12/1
By Henry ToThere are three arguments for this contrarian view British banker and politician Nathan Rothschild once said: "Buy when there's blood running in the streets." And blood is certainly spilling in the streets of the oil and gas industry.
Sign-up for Why crude oil will average $80 a barrel in 2015 investment picks
2014/12/2
By Henry ToThere are three arguments for this contrarian view British banker and politician Nathan Rothschild once said: "Buy when there's blood running in the streets." And blood is certainly spilling in the streets of the oil and gas industry.
Sign-up for UPDATE: Why crude oil will average $80 a barrel in 2015 investment picks
2014/12/1
By Henry ToThere are three arguments for this contrarian view British banker and politician Nathan Rothschild once said: "Buy when there's blood running in the streets." And blood is certainly spilling in the streets of the oil and gas industry.
Sign-up for UPDATE: Why crude oil will average $80 a barrel in 2015 investment picks
CPSI (NASDAQ: CPSI), a leading provider of health information systems and services, and its wholly owned subsidiary, TruBridge, today announced that they are leveraging IBM technology to develop and deliver predictive analytics to rural and community hospitals.
Sign-up for CPSI and TruBridge Collaborate with IBM to Deliver Predictive Analytics at the Point of Patient Care investment picks
- IRIDICA has the potential to change how pathogens that cause serious infections, such as sepsis and pneumonia, are detected and identified - May provide doctors with information needed to start treating those who are critically ill with appropriate therapies sooner - May help reduce the use of broad-spectrum antibiotics, a leading cause of antibiotic resistance ABBOTT PARK, Ill., Dec.
Sign-up for Abbott's Pioneering, Infectious Disease Testing Platform, IRIDICA, Now Available in Europe investment picks
http://media.marketwire.com/attachments/200906/438886_oracleresized.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155407&ProfileId=051205&sourceType=1 REDWOOD SHORES, CA --
Sign-up for Kohl's Sets Foundation for Future Growth With Oracle Retail investment picks
Company to Distribute 80.1% Ownership in REIT to Shareholders Remaining 19.9% Ownership in REIT Used to Retire Additional Windstream Debt Company to Hold Special Stockholder Meeting in February 2015 LITTLE ROCK, Ark., Dec.
Sign-up for Windstream Provides Update on REIT Spinoff investment picks
SOUTH SAN FRANCISCO, Calif., Dec.
Sign-up for Calithera Biosciences Gains Exclusive, Worldwide License to Mars Symbioscience's Arginase Inhibitors investment picks
RESEARCH TRIANGLE PARK, N.C., Oct.
Sign-up for BioCryst Announces Late Breaker Presentation of OPuS-1 Phase 2 Trial Results at the 23rd EADV Congress investment picks
SEATTLE , Nov.
Sign-up for Alaska Airlines Earns Top Score in 2015 Corporate Equality Index investment picks
2014/11/12
SHANGHAI , Nov.
Sign-up for WuXi AppTec Announces Enhanced Genomics Services for Chinese Researchers investment picks
New Store Underscores Deckers Brands' Commitment to Omni-Channel Consumer Experience GOLETA, Calif.
Sign-up for UGG® Opens First High-Tech Concept Store In Washington, D.C. Area investment picks
- AbbVie Presents for the First Time Results from the Venetoclax Phase 2 Program in Acute Myelogenous Leukemia - Study Evaluated Preliminary Efficacy of Venetoclax in 32 Patients with Relapsed/Refractory Acute Myelogenous Leukemia and as Frontline Therapy in Patients Unfit for Intensive Treatment NORTH CHICAGO, Ill.
Sign-up for AbbVie Presents Results from Phase 2 Study of Investigational Compound Venetoclax (ABT-199/GDC-0199) in Acute Myelogenous Leukemia at the 56th American Society of Hematology Annual Meeting investment picks
2014/12/4
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0982727001&sourceType=1 http://media3.marketwire.com/logos/20121210-meg1210.jpg CALGARY, ALBERTA --
Sign-up for MEG Energy announces $1.2 billion 2015 capital budget investment picks
2015/1/4
By Jack Nicas Drones made the leap from the battlefields to American backyards in 2014, raising concerns about air safety, privacy and regulation.
Sign-up for More Drones in 2015, But Not Drone Rules -- Corporate Outlook investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Popular Articles From: Epizyme DOT1L Inhibitor EPZ-5676 Shows Clinical and Biological Activity in Adult Patients with Acute Leukemias in Phase 1 Trial to More Drones in 2015, But Not Drone Rules -- Corporate Outlook
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent